<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00620542</url>
  </required_header>
  <id_info>
    <org_study_id>D356IC00001</org_study_id>
    <secondary_id>2007-004000-13</secondary_id>
    <nct_id>NCT00620542</nct_id>
  </id_info>
  <brief_title>CRESTOR Athero Imaging Head to Head IVUS Study</brief_title>
  <acronym>SATURN</acronym>
  <official_title>Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin (SATURN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      A 104-week, randomized, double-blind, parallel group, multi-center Phase IIIb study comparing
      the effects of treatment with rosuvastatin 40 mg or atorvastatin 80 mg on atherosclerotic
      disease burden as measured by intravascular ultrasound in patients with coronary artery
      disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to End of Study (Week 104) in Percent Atheroma Volume (PAV)</measure>
    <time_frame>End of study (Week 104)</time_frame>
    <description>Change in PAV computed as PAV(Week 104)-PAV(baseline) where PAV is calculated as:
[sum(EEMcsa-LUMENcsa)/sum EEMcsa]*100 where EEMcsa is the cross-sectional area of the external elastic membrane and LUMENcsa is the cross-sectional area of the lumen, as measured by intravascular ultrasound IVUS of a coronary artery in patients with CAD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numbers of Patients Showing Regression in PAV</measure>
    <time_frame>End of study (Week 104)</time_frame>
    <description>Regression defined as a change from baseline in PAV &lt; 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to End of Study (Week 104) in Total Atheroma Volume (TAV)</measure>
    <time_frame>End of study (Week 104)</time_frame>
    <description>Change in TAV, as measured by IVUS, computed as TAV(Week 104)-TAV(baseline) where TAV is the sum(EEMcsa-LUMENcsa)/n. n is the number of cross-sections measured. TAV for each patient is calculated as the average area of atheroma per cross-section multiplied by the median number of cross-sections measured for all patients in the analysis population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of Patients Showing Regression in TAV</measure>
    <time_frame>End of study (Week 104)</time_frame>
    <description>Regression defined as a change from baseline in TAV &lt; 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol Blood Level</measure>
    <time_frame>104 weeks</time_frame>
    <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C Blood Level</measure>
    <time_frame>104 weeks</time_frame>
    <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL-C Blood Level</measure>
    <time_frame>104 weeks</time_frame>
    <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides Blood Level</measure>
    <time_frame>104 weeks</time_frame>
    <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-HDL-C Blood Level</measure>
    <time_frame>104 weeks</time_frame>
    <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL-C/HDL-C Blood Level</measure>
    <time_frame>104 weeks</time_frame>
    <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol/HDL-C Blood Level</measure>
    <time_frame>104 weeks</time_frame>
    <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-HDL-C/HDL-C Blood Level</measure>
    <time_frame>104 weeks</time_frame>
    <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein B Blood Level</measure>
    <time_frame>104 weeks</time_frame>
    <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apolipoprotein A-1 Blood Level</measure>
    <time_frame>104 weeks</time_frame>
    <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apoliprotein B/Apolipoprotein A-1 Blood Level</measure>
    <time_frame>104 weeks</time_frame>
    <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VLDL-C During the 104 Week Treatment Period</measure>
    <time_frame>104 weeks</time_frame>
    <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2333</enrollment>
  <condition>Coronary Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 20 mg distributed in 2-week run-in period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 40 mg distributed in 2-week run-in period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 40 mg distributed in core 2-year study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin 80 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atorvastatin 80 mg distributed in core 2-year study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>capsule, oral, once daily</description>
    <arm_group_label>Rosuvastatin 20 mg</arm_group_label>
    <arm_group_label>Rosuvastatin 40 mg</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>capsule, oral, one daily</description>
    <arm_group_label>Atorvastatin 40 mg</arm_group_label>
    <arm_group_label>Atorvastatin 80 mg</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical indication for coronary angiography

          -  Angiographic evidence of Coronary Artery Disease (CAD), as defined by at least 1
             lesion in a native coronary artery that has &gt;20% reduction in lumen diameter by visual
             estimation

          -  Left main coronary artery must have &lt;=50% reduction in lumen diameter by visual
             estimation

          -  LDL-C &gt;100 mg/dL (2.6 mmol/L) for patients with no statin therapy in the past 4 weeks;
             LDL-C &gt;80mg/dL (2.08mmol/L) for patients on therapy in the past 4 weeks

        Exclusion Criteria:

          -  Use of certain lipid-lowering medication for more than 3 months within the previous 12
             months. Longer periods of treatment are not permitted because of the potential effects
             of such therapy on coronary atherosclerosis.

          -  Patients who have symptoms consistent with moderate or greater severity of Congestive
             Heart Failure (CHF).

          -  Clinically significant heart disease which, in the opinion of the Principal
             Investigator (or designee), is likely to require coronary bypass surgery, cardiac
             transplantation, surgical repair and/or replacement during the course of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen J Nicholls, MBBS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic Foundation, Cardiovascular Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greeley</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ft Lauderdale</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elkhart</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hammond</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Merrillville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valparaiso</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ashland</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Takoma Park</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Midland</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Muskegon</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Cloud</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Johnson City</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Williamsville</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perrysburg</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hillsboro</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wormleysburg</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oak Ridge</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cap. Fed.</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe-argentina</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Corrientes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Lambton Heights</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brugge</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cariacica</city>
        <state>ES</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vitoria</city>
        <state>ES</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uberlandia</city>
        <state>MG</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cuiaba</city>
        <state>MT</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Le Plessis-robinson</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quincy Sous Senart</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Arezzo</city>
        <state>AR</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sesto San Giovanni</city>
        <state>Milano</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Siena</city>
        <state>SI</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>D.F</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Puebla</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Queretaro</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tijuana</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kedzierzyn Kozle</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zabrze</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krasnogorsk</city>
        <state>Moscow Region</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Badalona</city>
        <state>Cataluna</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <state>Comunidad de Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2008</study_first_submitted>
  <study_first_submitted_qc>February 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <results_first_submitted>May 22, 2012</results_first_submitted>
  <results_first_submitted_qc>May 22, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 25, 2012</results_first_posted>
  <last_update_submitted>July 11, 2012</last_update_submitted>
  <last_update_submitted_qc>July 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>2333 Coronary Artery Disease (CAD) patients with clinical indication for coronary angiography were randomized to Part A, the 2-week run-in period. Of these, 1578 patients were treated and 1385 completed Part A. The 1385 patients completing Part A were then randomized to Part B the core study period of 104 weeks of treatment.</recruitment_details>
      <pre_assignment_details>Angiography was performed to determine if patients were qualified to continue in the study based on protocol-specified angiographic criteria. Patients who satisfied all inclusion and exclusion criteria had an Intravascular Ultrasound (IVUS) performed within 2 weeks of the qualifying angiography.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rosuvastatin 20 mg</title>
          <description>2 week run-in period</description>
        </group>
        <group group_id="P2">
          <title>Atorvastatin 40 mg</title>
          <description>2 week run-in period</description>
        </group>
        <group group_id="P3">
          <title>Rosuvastatin 40 mg</title>
          <description>2 year core study</description>
        </group>
        <group group_id="P4">
          <title>Atorvastatin 80 mg</title>
          <description>2 year core study</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A (Run-in - 2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1167">Of 1167 randomized, N=783 received treatment.</participants>
                <participants group_id="P2" count="1166">Of 1166 randomized, N=795 received treatment.</participants>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="783"/>
                <participants group_id="P2" count="795"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="695"/>
                <participants group_id="P2" count="690"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="472"/>
                <participants group_id="P2" count="476"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="406"/>
                <participants group_id="P2" count="409"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Safety reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>IVUS not available</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B (2 Year Core Study)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="694">Of 694 patients randomized, N=691 received treatment.</participants>
                <participants group_id="P4" count="691">Of 691 patients randomized, N=689 received treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="691"/>
                <participants group_id="P4" count="689"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intent-to-treat Population</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="520">Patients who received treatment and had a baseline and end of study (Week 104) IVUS</participants>
                <participants group_id="P4" count="519">Patients who received treatment and had a baseline and end of study (Week 104) IVUS</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="546"/>
                <participants group_id="P4" count="547"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="148"/>
                <participants group_id="P4" count="144"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="49"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="54"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Safety reasons</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study specific discontinuation criteris</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>IVUS not available</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rosuvastatin 40 mg</title>
          <description>2 years</description>
        </group>
        <group group_id="B2">
          <title>Atorvastatin 80 mg</title>
          <description>2 years</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="520"/>
            <count group_id="B2" value="519"/>
            <count group_id="B3" value="1039"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="402"/>
                    <measurement group_id="B2" value="395"/>
                    <measurement group_id="B3" value="797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age (yrs) at Week 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.4" spread="8.60"/>
                    <measurement group_id="B2" value="57.9" spread="8.50"/>
                    <measurement group_id="B3" value="57.6" spread="8.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="379"/>
                    <measurement group_id="B2" value="386"/>
                    <measurement group_id="B3" value="765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to End of Study (Week 104) in Percent Atheroma Volume (PAV)</title>
        <description>Change in PAV computed as PAV(Week 104)-PAV(baseline) where PAV is calculated as:
[sum(EEMcsa-LUMENcsa)/sum EEMcsa]*100 where EEMcsa is the cross-sectional area of the external elastic membrane and LUMENcsa is the cross-sectional area of the lumen, as measured by intravascular ultrasound IVUS of a coronary artery in patients with CAD.</description>
        <time_frame>End of study (Week 104)</time_frame>
        <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 40 mg</title>
            <description>Part B: Rosuvastatin 40 mg for core study - 2 years</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 80 mg</title>
            <description>Part B: Atorvastatin 80 mg for core study - 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Study (Week 104) in Percent Atheroma Volume (PAV)</title>
          <description>Change in PAV computed as PAV(Week 104)-PAV(baseline) where PAV is calculated as:
[sum(EEMcsa-LUMENcsa)/sum EEMcsa]*100 where EEMcsa is the cross-sectional area of the external elastic membrane and LUMENcsa is the cross-sectional area of the lumen, as measured by intravascular ultrasound IVUS of a coronary artery in patients with CAD.</description>
          <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
          <units>Percent change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="520"/>
                <count group_id="O2" value="519"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.22" lower_limit="-1.52" upper_limit="-0.90"/>
                    <measurement group_id="O2" value="-0.99" lower_limit="-1.19" upper_limit="-0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numbers of Patients Showing Regression in PAV</title>
        <description>Regression defined as a change from baseline in PAV &lt; 0</description>
        <time_frame>End of study (Week 104)</time_frame>
        <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 40 mg</title>
            <description>Part B: Rosuvastatin 40 mg for core study - 2 years</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 80 mg</title>
            <description>Part B: Atorvastatin 80 mg for core study - 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers of Patients Showing Regression in PAV</title>
          <description>Regression defined as a change from baseline in PAV &lt; 0</description>
          <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="520"/>
                <count group_id="O2" value="519"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="356"/>
                    <measurement group_id="O2" value="328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to End of Study (Week 104) in Total Atheroma Volume (TAV)</title>
        <description>Change in TAV, as measured by IVUS, computed as TAV(Week 104)-TAV(baseline) where TAV is the sum(EEMcsa-LUMENcsa)/n. n is the number of cross-sections measured. TAV for each patient is calculated as the average area of atheroma per cross-section multiplied by the median number of cross-sections measured for all patients in the analysis population.</description>
        <time_frame>End of study (Week 104)</time_frame>
        <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 40 mg</title>
            <description>Part B: Rosuvastatin 40 mg for core study - 2 years</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 80 mg</title>
            <description>Part B: Atorvastatin 80 mg for core study - 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to End of Study (Week 104) in Total Atheroma Volume (TAV)</title>
          <description>Change in TAV, as measured by IVUS, computed as TAV(Week 104)-TAV(baseline) where TAV is the sum(EEMcsa-LUMENcsa)/n. n is the number of cross-sections measured. TAV for each patient is calculated as the average area of atheroma per cross-section multiplied by the median number of cross-sections measured for all patients in the analysis population.</description>
          <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
          <units>mm^3</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="520"/>
                <count group_id="O2" value="519"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.39" lower_limit="-7.52" upper_limit="-5.12"/>
                    <measurement group_id="O2" value="-4.42" lower_limit="-5.98" upper_limit="-3.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numbers of Patients Showing Regression in TAV</title>
        <description>Regression defined as a change from baseline in TAV &lt; 0</description>
        <time_frame>End of study (Week 104)</time_frame>
        <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 40 mg</title>
            <description>Part B: Rosuvastatin 40 mg for core study - 2 years</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 80 mg</title>
            <description>Part B: Atorvastatin 80 mg for core study - 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers of Patients Showing Regression in TAV</title>
          <description>Regression defined as a change from baseline in TAV &lt; 0</description>
          <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="520"/>
                <count group_id="O2" value="519"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="371"/>
                    <measurement group_id="O2" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol Blood Level</title>
        <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
        <time_frame>104 weeks</time_frame>
        <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 40 mg</title>
            <description>Part B: Rosuvastatin 40 mg for core study - 2 years</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 80 mg</title>
            <description>Part B: Atorvastatin 80 mg for core study - 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol Blood Level</title>
          <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
          <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="519"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.38" spread="1.24"/>
                    <measurement group_id="O2" value="144.05" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL-C Blood Level</title>
        <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
        <time_frame>104 weeks</time_frame>
        <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 40 mg</title>
            <description>Part B: Rosuvastatin 40 mg for core study - 2 years</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 80 mg</title>
            <description>Part B: Atorvastatin 80 mg for core study - 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>LDL-C Blood Level</title>
          <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
          <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="519"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.64" spread="1.00" lower_limit="1.00"/>
                    <measurement group_id="O2" value="70.18" spread="0.99" lower_limit="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HDL-C Blood Level</title>
        <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
        <time_frame>104 weeks</time_frame>
        <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 40 mg</title>
            <description>Part B: Rosuvastatin 40 mg for core study - 2 years</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 80 mg</title>
            <description>Part B: Atorvastatin 80 mg for core study - 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>HDL-C Blood Level</title>
          <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
          <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="519"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.43" spread="0.54" lower_limit="0.54"/>
                    <measurement group_id="O2" value="48.64" spread="0.53" lower_limit="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglycerides Blood Level</title>
        <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
        <time_frame>104 weeks</time_frame>
        <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 40 mg</title>
            <description>Part B: Rosuvastatin 40 mg for core study - 2 years</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 80 mg</title>
            <description>Part B: Atorvastatin 80 mg for core study - 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides Blood Level</title>
          <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
          <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="519"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.50" spread="2.44" lower_limit="2.44"/>
                    <measurement group_id="O2" value="126.58" spread="2.43" lower_limit="2.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-HDL-C Blood Level</title>
        <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
        <time_frame>104 weeks</time_frame>
        <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 40 mg</title>
            <description>Part B: Rosuvastatin 40 mg for core study - 2 years</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 80 mg</title>
            <description>Part B: Atorvastatin 80 mg for core study - 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Non-HDL-C Blood Level</title>
          <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
          <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="519"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.95" spread="1.15" lower_limit="1.15"/>
                    <measurement group_id="O2" value="95.41" spread="1.14" lower_limit="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL-C/HDL-C Blood Level</title>
        <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
        <time_frame>104 weeks</time_frame>
        <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 40 mg</title>
            <description>Part B: Rosuvastatin 40 mg for core study - 2 years</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 80 mg</title>
            <description>Part B: Atorvastatin 80 mg for core study - 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>LDL-C/HDL-C Blood Level</title>
          <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
          <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="519"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.02" lower_limit="0.02"/>
                    <measurement group_id="O2" value="1.50" spread="0.02" lower_limit="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol/HDL-C Blood Level</title>
        <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
        <time_frame>104 weeks</time_frame>
        <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 40 mg</title>
            <description>Part B: Rosuvastatin 40 mg for core study - 2 years</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 80 mg</title>
            <description>Part B: Atorvastatin 80 mg for core study - 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol/HDL-C Blood Level</title>
          <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
          <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="519"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" spread="0.03" lower_limit="0.03"/>
                    <measurement group_id="O2" value="3.08" spread="0.03" lower_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-HDL-C/HDL-C Blood Level</title>
        <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
        <time_frame>104 weeks</time_frame>
        <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 40 mg</title>
            <description>Part B: Rosuvastatin 40 mg for core study - 2 years</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 80 mg</title>
            <description>Part B: Atorvastatin 80 mg for core study - 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Non-HDL-C/HDL-C Blood Level</title>
          <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
          <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="519"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" spread="0.03" lower_limit="0.03"/>
                    <measurement group_id="O2" value="2.08" spread="0.03" lower_limit="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apolipoprotein B Blood Level</title>
        <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
        <time_frame>104 weeks</time_frame>
        <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 40 mg</title>
            <description>Part B: Rosuvastatin 40 mg for core study - 2 years</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 80 mg</title>
            <description>Part B: Atorvastatin 80 mg for core study - 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Apolipoprotein B Blood Level</title>
          <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
          <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="518"/>
                <count group_id="O2" value="519"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.55" spread="0.85" lower_limit="0.85"/>
                    <measurement group_id="O2" value="75.12" spread="0.85" lower_limit="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apolipoprotein A-1 Blood Level</title>
        <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
        <time_frame>104 weeks</time_frame>
        <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 40 mg</title>
            <description>Part B: Rosuvastatin 40 mg for core study - 2 years</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 80 mg</title>
            <description>Part B: Atorvastatin 80 mg for core study - 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Apolipoprotein A-1 Blood Level</title>
          <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
          <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="518"/>
                <count group_id="O2" value="519"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="146.81" spread="1.03" lower_limit="1.03"/>
                    <measurement group_id="O2" value="137.68" spread="1.02" lower_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apoliprotein B/Apolipoprotein A-1 Blood Level</title>
        <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
        <time_frame>104 weeks</time_frame>
        <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 40 mg</title>
            <description>Part B: Rosuvastatin 40 mg for core study - 2 years</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 80 mg</title>
            <description>Part B: Atorvastatin 80 mg for core study - 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>Apoliprotein B/Apolipoprotein A-1 Blood Level</title>
          <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
          <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
          <units>Ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="518"/>
                <count group_id="O2" value="519"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.01"/>
                    <measurement group_id="O2" value="0.56" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VLDL-C During the 104 Week Treatment Period</title>
        <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
        <time_frame>104 weeks</time_frame>
        <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
        <group_list>
          <group group_id="O1">
            <title>Rosuvastatin 40 mg</title>
            <description>Part B: Rosuvastatin 40 mg for core study - 2 years</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin 80 mg</title>
            <description>Part B: Atorvastatin 80 mg for core study - 2 years</description>
          </group>
        </group_list>
        <measure>
          <title>VLDL-C During the 104 Week Treatment Period</title>
          <description>Time-weighted average is calculated as the lipid value times the number of days since last lipid assessment, summed for all and divided by the number of days from Part B randomization to date of the last lipid evaluation.</description>
          <population>Intent-to-Treat population (patients received at least one dose of study drug and had pre-study and post-study IVUS).</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="519"/>
                <count group_id="O2" value="519"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.05" spread="0.45"/>
                    <measurement group_id="O2" value="25.03" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rosuvastatin 20 mg</title>
          <description>2 week run-in period</description>
        </group>
        <group group_id="E2">
          <title>Atorvastatin 40 mg</title>
          <description>2 week run-in period</description>
        </group>
        <group group_id="E3">
          <title>Rosuvastatin 40 mg</title>
          <description>2 year core study</description>
        </group>
        <group group_id="E4">
          <title>Atorvastatin 80 mg</title>
          <description>2 year core study</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="194" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="168" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Mitral Valve Incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis Coronary Artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Coronary Artery Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Coronary Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Coronary Artery Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Ischaemic Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Pericardial Rub</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Sinus Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Wolff-Parkinson-White Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital Coronary Artery Malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Hip Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Vertigo Positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Colitis Ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Colonic Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Erosive Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Gastric Polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia, Obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Device Malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Device Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Device Stimulation Issue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Hernia Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Thrombosis In Device</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Appendicitis Perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Dengue Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Groin Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Herpes Zoster Infection Neurological</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Pilonidal Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Puncture Site Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Staphylococcal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>In-Stent Coronary Artery Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Toxicity To Various Agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Coronary Artery Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Fractured Coccyx</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Heat Exhaustion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>In-Stent Arterial Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Intentional Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Limb Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Pelvic Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Post Procedural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Post Procedural Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Pseudomeningocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Thermal Burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Traumatic Lung Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Cardiac Stress Test Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Heart Rate Irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Liver Function Test Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Occult Blood Positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Type 2 Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Rotator Cuff Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Bone Loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Floating Patella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Foot Deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Groin Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Spinal Column Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Bladder Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Colon Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Extranodal Marginal Zone B-Cell Lymphoma (Malt Type)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Eyelid Tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Gallbladder Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Lung Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Lung Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Neoplasm Prostate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Throat Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Complicated Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Grand Mal Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Haemorrhage Intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Intracranial Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Dependence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Panic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Bladder Neck Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Calculus Bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Ureteric Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Vaginal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Nasal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Nasal Polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Pulmonary Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Sleep Apnoea Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary Arterial Stent Insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Intermittent Claudication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Subclavian Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Aortic Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Arterial Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Femoral Arterial Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Iliac Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis Superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="210" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="213" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="65" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="91" subjects_at_risk="689"/>
              </event>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="783"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="795"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="691"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="689"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

